Could a new vaccine stop genital herpes? early trial begins

NCT ID NCT05432583

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 29 times

Summary

This early-stage trial tests a new vaccine designed to prevent genital herpes caused by HSV-2 (and possibly HSV-1). About 318 healthy adults aged 18-55 will receive different doses to check safety and immune response. The goal is to see if the vaccine is safe and triggers the body's defenses against the virus.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENITAL HERPES SIMPLEX TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Accellacare PMG Research Wilmington LLC

    Wilmington, North Carolina, 28401, United States

  • Accellacare Raleigh Medical Group

    Raleigh, North Carolina, 27609, United States

  • Alliance for Multispecialty Research, LLC

    Tempe, Arizona, 85281, United States

  • CTI Clinical Research Center

    Cincinnati, Ohio, 45212, United States

  • Great Lakes Clinical Trials - Flourish Research

    Chicago, Illinois, 60640, United States

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.